Trelegy Ellipta Will Be the First 3-in-1 Inhaler for COPD

January 2018

Trelegy Ellipta (TREL-eh-gee) will be the first "three-in-one" inhaler for COPD.

Trelegy combines two long-acting inhaled bronchodilators, umeclidinium and vilanterol...and the corticosteroid fluticasone furoate. It's a dry-powder inhaler that's given as a single puff once daily.

Expect Trelegy to be saved for COPD patients who have exacerbations while taking two long-acting bronchodilators...or who also have asthma.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Help Your Pharmacy Survive Insurance Audits
Calculations Stop Common Pharmacy Calculation Errors in Their Tracks
COPD Trelegy Ellipta Will Be the First 3-in-1 Inhaler for COPD
Insulin Stay Sharp for Potential Errors With Insulin Pens
Hypertension Set Patients Up for Success With Blood Pressure Monitoring
Topicals Overcome Dispensing Hurdles With Topical Steroids
Diabetes Meds Help Patients Stay Safe With Sulfonylureas
Cough & Cold Avoid Pitfalls With Cough Remedies
Med Safety Take Steps to Keep Patients Safe From "Drugged Driving"
Hypothyroidism Prevent Mishaps With Hypothyroid Meds
Influenza Anticipate Some Patients Getting Antivirals to Treat the Flu
Substance Use Disorder Avoid Dispensing Problems With Naltrexone for Opioid Dependence

Trelegy Ellipta Will Be the First 3-in-1 Inhaler for COPD

Practical advice for a better career, with unlimited access to CE

Table of Contents